Cdc25A promotes cell survival by stimulating NF-κB activity through IκB-α phosphorylation and destabilization

Biochemical and Biophysical Research Communications

Volumn 420, Issue 2, 2012, Pages 293-296

  Hong, Hey Young ^a   Choi, Jiyeon ^a   Cho, Young Wook ^b   Kim, Byung Chul ^a  

^a Kangwon National University   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

Apoptosis; Cdc25A; I B ; NF B; Ubiquitination

Indexed keywords

CELL DIVISION CYCLE 25A; CISPLATIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOPROTEIN PHOSPHATASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CDC25 PHOSPHATASES; CELL NUCLEUS; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; I-KAPPA B KINASE; NF-KAPPA B; PHOSPHORYLATION; TRANSCRIPTION FACTOR RELA;

EID: 84862806583     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.152     Document Type: Article

References (15)

1. Rudolph J. Cdc25 phosphatases: structure, specificity, and mechanism. Biochemistry 2007, 46:3595-3604.
2. De Wulf P., Montani F., Visintin R. Protein phosphatases take the mitotic stage. Curr. Opin. Cell Biol. 2009, 6:806-815.
3. Blomberg I., Hoffmann I. Etopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E-and cyclin A-dependent kinases. Mol. Cell Biol. 1999, 19:6183-6194.
4. Bartek J., Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 2001, 490:117-122.
5. Ray D., Kiyokawa H. CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res. 2008, 68:1251-1253.
6. Boutros R., Lobjois V., Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat. Rev. 2007, 7:495-507.
7. Kristjansdottir K., Rudolph J. Cdc25 phosphatases and cancer. Chem. Biol. 2004, 11:1043-1051.
8. Cangi M.G., Cukor B., Soung P., Signoretti S., Moreira G., Ranashinge M., Cady B., Pagano M., Loda M. Role of the Cdc25A phosphatase in human breast cancer. J. Clin. Invest. 2000, 106:753-761.
9. Brault L., Bagrel D. Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells. Life Sci. 2008, 82:315-323.
10. Kumar A., Takada Y., Boriek A.M., Aggarwal B.B. Nuclear factor-kappaB: its role in health and disease. J. Mol. Med. 2004, 82:434-448.
11. Baldwin A.S. Series introduction: the transcription factor NF-kappaB and human disease. J. Clin. Invest. 2001, 107:3-6.
12. Wang C.Y., Guttridge D.C., Mayo M.W., Baldwin A.S. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 1999, 19:5923-5929.
13. Gilmore T.D. Introduction to NF-κB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684.
14. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 2000, 18:621-663.
15. Kim K., Lu Z., Hay E.D. Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol. Int. 2002, 26:463-476.